Tag

A1c

All articles tagged with #a1c

health10 days ago•7 min saved

Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial

Lilly reports positive topline results from TRANSCEND-T2D-1, a Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist (GIP, GLP-1, glucagon), showing up to a 2.0% reduction in A1C and about 17% body-weight loss at 40 weeks versus placebo, with dose-dependent effects and continued weight loss through the treatment period. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting) largely during dose escalation, with some dysesthesia but generally manageable. Results met primary and key secondary endpoints and will be detailed at the ADA Scientific Sessions in June; Lilly plans to publish additional data from the retatrutide program over the next year.

via Eli Lilly|

#a1c #health #phase-3

business10 days ago•4 min saved

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial

Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.

via CNBC|

#a1c #business #eli-lilly

health2 years ago•4 min saved

The Long-Term Consequences of Type 2 Diabetes in Children

Children with type 2 diabetes face a high incidence of vascular complications as they age into young adulthood, with an 80% incidence of at least one complication during up to 15 years of follow-up. Arterial stiffness and worsened cardiac function often appear in these children within 2-5 years of diagnosis and seem driven in part by the development of hypertension and worsening A1c levels. The dire prognosis is a reason to aggressively treat these patients with antidiabetic medications from drug classes with proven cardiovascular disease protection, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists.

via Medscape|

#a1c #antidiabetic-medications #cardiovascular-disease